Sumitomo Mitsui Trust Holdings, Inc. I Mab Transaction History

Sumitomo Mitsui Trust Holdings, Inc.

5 transactions

Quarter	Operation	Price Per share	shares change	shares Held
Q2 2022 Jul 26, 2022	SELL	$8.27 - $18.43 $701,982 - $1.56 Million	-84,883 Closed	0 $0
Q1 2022 Apr 27, 2022	BUY	$12.54 - $46.93 $69,948 - $261,775	5,578 Added 7.03%	84,883 $1.38 Million
Q4 2021 Feb 02, 2022	BUY	$45.28 - $74.5 $75,798 - $124,713	1,674 Added 2.16%	79,305 $3.76 Million
Q3 2021 Oct 25, 2021	BUY	$57.18 - $84.43 $180,860 - $267,052	3,163 Added 4.25%	77,631 $5.63 Million
Q2 2021 Aug 02, 2021	BUY	$47.86 - $83.95 $3.56 Million - $6.25 Million	74,468 New	74,468 $6.25 Million

16.4M

1.9K

Ticker IMAB
Exchange NASDAQ
Sector Healthcare
Industry Biotechnology
Shares Outstandng 83,098,800
Market Cap $108M
Description
I-Mab, a clinical stage biopharmaceutical company, discovers, develops, and commercializes biologics to treat cancer and autoimmune disorders. It is developing Felzartamab, a CD38 antibody that is in Phase 1b/2a for patients with membranous nephropathy; Eftansomatropin alfa, a long-acting human growth hormone, which has completed Phase 3 clinica...

Get notified when there are updates to the investment portfolio of Sumitomo Mitsui Trust Holdings, Inc., based on Form 13F filings with the SEC.

Stay updated on Sumitomo Mitsui Trust Holdings, Inc. with notifications on news.